Neuronetics, Inc. STIM
Medical/Dental Instruments · IPO 2018 · data as of November 13, 2026
Neuronetics, Inc. (STIM) is a healthcare company listed in the US with a market value of about $134M. In the twelve months to September 30, 2026 it had revenue of $160M and net income of -$23M, a net margin of -14.4%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 25% a year, a 5-year average ROIC of -24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 65% below the current price.
About Neuronetics
Neuronetics is listed in the US and classified in medical/dental instruments, IPO year 2018. Revenue went from $34M in 2016 to $149M in 2025, growth of about 17.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 145% over three years (dilution for shareholders). It spends 4% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160M | $149M | $75M | $71M | $65M | $55M | $49M | $63M | $53M | $40M | $34M |
| Net income | -$23M | -$39M | -$44M | -$30M | -$37M | -$31M | -$27M | -$29M | -$24M | -$16M | -$11M |
| Free cash flow | -$10M | -$21M | -$32M | -$34M | -$34M | -$30M | -$29M | -$31M | -$22M | -$12M | -$9M |
| EPS (diluted) | $-0.33 | $-0.59 | $-1.38 | $-1.05 | $-1.38 | $-1.22 | $-1.46 | $-1.58 | $-2.69 | $-86.34 | $-76.95 |
| Net margin | -14.4% | -26.2% | -58.4% | -42.3% | -57.0% | -56.4% | -55.8% | -46.4% | -45.7% | -39.7% | -32.8% |
| ROIC | — | -22.0% | -24.8% | -25.0% | -28.6% | -17.5% | -27.6% | -25.9% | -15.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $6.00, 332% above the current price; targets range from $5.00 to $7.00; the consensus rating is “Strong buy”; expected EPS is $-0.46 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Neuronetics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 65% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Neuronetics pay a dividend?
Not currently.
Is Neuronetics a good stock to buy?
We do not give buy or sell advice. Neuronetics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.